Author(s): S. Rekhraj, J. Kinross, S. Prabhudesai, A. Darzi and P. Ziprin
Page: [511 - 519] Pages: 9
* (Excluding Mailing and Handling)
Recent evidence has suggested improved outcomes following incorporation of intraperitoneal chemotherapy administration with intravenous systemic chemotherapy as first-line treatment of small volume residual epithelial ovarian cancer. This review focuses on the mechanism of actions of the chemotherapeutic drugs and reviews the possible reasons for the superior outcomes of intraperitoneal chemotherapy.
Keywords: Intraperitoneal chemotherapy, cisplatin, carboplatin, paclitaxel, ovarian cancer management
Download PDF Flyer